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Introduction: By regulating cell functions such as growth, survival,
motility/migration, and invasion, the c-mesenchymal-epithelial tran-
sition (c-MET) receptor tyrosine kinase/hepatocyte growth factor
(HGF) axis accounts for a critical pathway in malignant pleural
mesothelioma.
Methods: Overall survival correlations of c-MET and phospho-c-
MET immunostainings were investigated in 157 malignant pleural
mesothelioma patients for whom paraffin-embedded specimens
were referred to our center for pathological diagnosis certification
(MESOPATH French National group). Subcellular localization of
the activated c-MET receptor after HGF stimulation was assessed in
nontumorogenic cell lines.
Results: Positive c-MET expression was found in 119 samples
(75.8%), more frequently in the epithelioid subtype (p  0.0001).
Among those 119 positive c-MET specimens, 77 (64.7%) were also
positive for phospho-c-MET. Both c-MET and phospho-c-MET
scoring were independent of patient gender or age. Phospho-c-MET
scoring or localization did not associate with survival. Conversely,
patients with a c-MET immunohistochemical staining intensity
higher than 1, but exclusively confined to plasma membrane, had a
median overall survival of 25 months versus 13 months for all other
patients. Only exclusive plasma membrane staining remained sig-
nificantly associated with a worse prognosis in multivariate analysis
(hazard ratio  2.9, 95% confidence interval 1.0–8.2, p  0.043).
Using the HBEC3 immortalized epithelial cell lines treated with
HGF, we showed the physiological relevance of phospho-c-MET
nuclear translocation.
Conclusions: Our results lighten that, disregarding the intracellular
c-MET receptor traffic, only c-MET plasma membrane localization
could be a relevant prognosis biomarker in malignant pleural me-
sothelioma. Whether patients with c-MET plasma membrane immu-
nostaining could beneficiate from c-MET-targeted therapies remains
to be established in prospective trials.
Key Words: Malignant pleural mesothelioma, c-MET, HGF,
Phospho-c-MET.
(J Thorac Oncol. 2012;7: 599–606)
Malignant pleural mesothelioma (MPM) is linked toasbestos exposure with an attributable risk fraction for
occupational asbestos exposure in men usually exceeding
80%. MPM is an aggressive malignant tumor with a poor
prognosis. The median overall survival (OS) ranged from 10
months with older regimens to 14 months with pemetrexed-
based chemotherapy. As the incidence of MPM is anticipated
to increase worldwide during the first half of this century,
tumor biomarkers could be greatly helpful to predict progno-
sis of patients with MPM and define adapted therapeutics.
Mesenchymal-epithelial transition (MET) is recognized
as an oncogene that encodes for an activated version of the
hepatocyte growth factor (HGF) tyrosine kinase receptor.
Overexpression of the c-MET receptor (80%) is commonly
reported in MPM tumor tissues,1–5 and c-MET gene muta-
tions (16%) have also been reported,2,5 suggesting that this
receptor promotes a critical pathway for MPM, i.e., invasion
and resistance to apoptosis.6 Such hypothesis is strengthened
by data showing that the exposure of normal mesothelioma
cells to asbestos fibers induced c-MET expression.7 However,
c-MET-dependent cellular mechanisms involved in the MPM
carcinogenesis are still misunderstood. It is well described
that HGF, secreted by stromal cells, binds to c-MET receptor
leading to its autophosphorylation8 and consequently to the
activation of a number of signaling pathways, including
phosphoinositide-3-kinase (PI-3K), Ras-Rac/Rho, Ras-mito-
gen-activated protein kinase, and phospholipase C path-
ways.9 Hence, c-MET receptor controls not only several
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physiological cellular processes such as cell mitosis or tissue
regeneration but also abnormal processes such as cell uncon-
trolled proliferation in neoplasia, cell spreading and migra-
tion, and essential functions in transformation multistep pro-
cess10 (for review see Ref. 11). It is worse known that, after
HGF stimulation, c-MET is rapidly internalized to early
endosomes and translocates to the nucleus.2,8,12 The function
of c-MET in the nucleus is controversial. Some work dem-
onstrated that c-MET must translocate to the nucleus to
initiate calcium signals,8 while other authors reported a direct
interaction of c-MET and PAX5, a transcription factor, in the
nuclear compartment. Further investigations are needed to
better understand these processes, their consequences in
MPM carcinogenesis, and the clinical consequences of c-
MET overexpression or subcellular localization. We aimed to
analyze the prognostic implications of both c-MET and its
activated form, phospho-c-MET expression and their respec-
tive subcellular localization in a series of 157 malignant
mesothelioma (MM) specimens referred in our center for
expert centralized pathological diagnosis certification.
PATIENTS and METHODS
Patients
A paraffin-embedded tissue block was sent to the
MESOPATH group for pathological diagnosis certification
process. Clinical data centralized by the National Mesotheli-
oma Registry (MESONAT) located in Caen University Hos-
pital were mandatory for such certification procedure and
prospectively collected, including demographic variables, oc-
cupational exposure, diagnosis procedure, and International
Mesothelioma Interest Group clinical tumor node metastasis
staging, when assessable for patients who have been staged
by a surgical procedure. Date of death was obtained by
systematic request of the referral center to the National
registry database to public records offices.13,14
Histological Examination and MPM Diagnosis
Histological examination of the 157 cases referred to
MESOPATH group was performed on tissue fixed in 4%
buffered formalin, routinely processed, and subsequently em-
bedded with paraffin. A representative 3-m section was cut
from each case and stained with hematoxylin, eosin, and
safran. In parallel, tumor paraffin-embedded slices of 3-m
slices were tested for calretinin, WT1, EMA, CK5/6, TTF-1,
and CEA expression, markers allowing MPM diagnosis cer-
tification by MESOPATH group as previously published.15
Histopathological international classification system (World
Health Organization 2004) for mesothelioma tumors was
used. All slides were examined by three experts from the
MESOPATH group, blind to the pathological diagnosis pro-
posed by the referral pathologist and also blind to both
asbestos exposure and clinical context. Slides giving discor-
dant diagnosis were reviewed by the whole expert panel using
multihead microscope, and a final pathological diagnosis was
retained by consensus according to the diagnosis criteria
previously reported.
c-MET and Phospho-c-MET
Immunohistochemistry and Scoring
Tumor paraffin-embedded blocks were cut into 3-m
slices. Slides were deparaffinized in toluene and rehydrated
using standard techniques. After pretreatment with ethylene-
diaminetetraacetic acid (EDTA) buffer (pH 9.0, 20 minutes,
100°C), slides were incubated in 3% H2O2 for 5 minutes and
then in 0.5% Tween (T)-phosphate-buffered saline enriched
by 5% bovine serum albumin for 60 minutes. Slides were
incubated overnight at 4°C with anti-c-MET (R&D Systems,
Abingdon, United Kingdom; 1:400) or antiphospho-Y1349-
c-MET (R&D Systems; 1:100) and then revealed using the
LSAB (Dako, Glostrup, Denmark) or Novolink (Menarini,
Rungis Cedex, France) kits, respectively. Positive internal
controls were systematically evaluated (normal epithelial
cell). Negative controls omitted the primary antibody.
All slides were examined without knowledge of the
individual patient data. Each cell was scored as 0, 1, 2, or 3,
which corresponded to negative, weak, moderate, or strong
staining intensities when compared with the internal control.
Percentage of stained cell was counted and a final histochem-
ical score calculated by multiplying the products of staining
intensities (0–3) and distribution (0–100%) from all parts of
the slide; therefore, this H-score range from 0 to 300. Semi-
quantitative H-scores were studied as continuous variables,
without any predetermined cutoff.
HBEC3 Cells Culture and Treatment
HBEC3 bronchial cells, immortalized by constitutive
expression of cyclin-dependent kinase 4 and human telomer-
ase reverse transcription, were kindly provided by Dr. Mi-
chae¨l White (UT Southwestern Medical Centre, Dallas,
TX).16 Cells were seeded on cover slips (immunofluores-
cence) or 175 cm2 flask (subcellular fraction) at the density of
7000 cells per well (24-well plate) and maintained at 37°C
under 5% CO2 atmosphere until cells raised 70% of conflu-
ence in Keratinocyte-SFM supplemented with EGFr (0.2
ng/ml), bovine pituitary extract (BPE) (25 g/ml), antibiotics
(100 IU/ml penicillin; 100 g/ml streptomycin; and 50 g/ml
kanamycin), and fungicide (0.25 g/ml amphotericin B).
Cells were then cultivated 24 hours in presence of KSFM
devoid of EGFr and BPE before be treated or not with HGF
(40 ng/ml) for 5, 10, 15, or 20 minutes.
Staining of HBEC3 and HBEC3RasV12 Cells for
Confocal Microscopy
Immunofluorescence studies were performed according
to standard protocols (available on request) with c-MET
(1:50), phospho-c-MET (1:50), or alpha-tubulin (1:100) an-
tibodies and Texas red-labeled antirabbit, mouse, or goat
secondary antibody (1:100). Negative controls omitted the
primary antibody. Immunocytochemistry staining was visu-
alized with a confocal laser scanning fluorescence micro-
scope (FluoView FV1000, Olympus) at the appropriate ex-
citation and emission wavelengths. Images were captured by
using the FV1000 software and processed with a FV10-
ASW-1.7 viewer.
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Preparation of HBEC3 Cells Membrane,
Cytosolic and Nuclear Fractions
Cell layer was washed with cold phosphate-buffered
saline, cells were trypsinized, and the fraction was isolated
according to the adaptive procedure of both Hurst et al.17 and
Dignam et al.18 Cells were suspended in an ice-cold lysis
buffer (20 mM HEPES, 20 mM NaCl, 0.5% Nonidet, pH 8.0,
supplemented with 0.5 mm phenylmethanesulfonyl fluoride,
1 mm dithiothreitol (DTT), and a mixture of antiproteases—
antipain, aprotinin, leupeptin, and pepstatin A—at a final
concentration of 1 g/ml). Homogenates were centrifugated
at 10,000g, room temperature for 1 minute, and the superna-
tant (cytoplasmic fraction) isolated. Pellets were resuspended
in an ice-cold nuclear pellet extraction buffer (20 mM
HEPES, 420 mM NaCl, 1.5 mM MgCl2, 25% glycerol, 0.2
mM EDTA, pH 7.9, supplemented with 0.5 mm phenylmeth-
anesulfonyl fluoride, 1 mm DTT, and a mixture of antipro-
teases—antipain, aprotinin, leupeptin, and pepstatin A—at a
final concentration of 1 g/ml), incubated 30 minutes at 4°C,
centrifugated at 10,000g, room temperature for 1 minute, and
the supernatant (nuclear fraction) diluted to low salt concen-
tration by adding two volumes of 20 mM HEPES. Finally,
pellets were resuspended into ice-cold homogenization buffer
(20 mm Tris-HCl, pH 7.2, 1 mm EDTA, 250 mm sucrose,
supplemented with 0.1 mm phenylmethanesulfonyl fluoride,
2 mm benzamidin, and a mixture of antiproteases—antipain,
aprotinin, leupeptin, and pepstatin A—at a final concentration
of 1 g/ml), homogenized by several passages through 25-
gauge needle, and then centrifuged at 100,000g, 4°C for 1
hour. Pellets (membrane fraction) were resuspended in ice-
cold complete homogenization buffer. Purity of each subcel-
lular fraction was checked by assaying the contamination of
a cell compartment by another, detecting in each fraction
c-jun (a nuclear protein), calpain (a cytoplasmic protein), and
calnexin (a transmembrane protein) presence.
Western Immunoblotting
HBEC3 subcellular fraction was heat denaturized and 10
g protein resolved by 10% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis. After protein electrotransfer, nitrocel-
lulose membranes were blocked with Tris-buffered saline and
0.1% Tween-20 with 5% wt/vol bovine serum albumin for 1
hour at room temperature. For immunodetection, blocked mem-
branes were incubated overnight at 4°C with c-MET antibody
(R&D Systems; 1:1500), phospho-c-MET (R&D Systems;
1:200), in Tris-buffered saline, 0.1% Tween-20, 0.1% wt/vol
BSA. The immunoreactive bands were detected using a mouse
antirabbit IgG-horseradish peroxidase complex (SantaCruz,
Heidelberg, Germany) and the enhanced chemiluminescence
Advance Western Blotting Detection Kit (Amersham Biosci-
ences). Blots were then stripped at 58°C for 30 minutes and
reprobed with c-jun (Cell signaling, 1:1000), calpain (Cell sig-
naling, 1:1000), or calnexin (Cell Signaling, Danvers, MA;
1:1000) for normalizing nuclear, cyoplasmic, and membrane
fractions, respectively. The immunoblots were scanned on the
ProXPRESS Proteomic Imaging System (Perkin Elmer Life
Science, Boston, MA) and analyzed with the TotalLab Image
Analysis software (Nonlinear Dynamics Ltd., Newcastle, United
Kingdom).
Statistical Analysis
OS was defined as the time in months from the initial
biopsy to the date of last news or to the date of cutoff—
December 31, 2009. OS was estimated for all demographic,
clinical, or molecular variables according to the Kaplan-
Meier nonparametric method, and the rates in each group
were compared with the log-rank stratified test. The most
promising variables associated to OS in univariate analysis
(log-rank test p value 0.10) were conserved in the multi-
variate Cox regression model to compute adjusted hazard
ratios (HRs). Statistical significance was set at p  0.05.
Two-sided Fisher’s exact test or 2 tests were used to
compare molecular and clinical characteristics. Data were
analyzed with SAS software, version 9.1.3 (SAS Software
System, SAS Institute Inc., Cary, NC).
RESULTS
Population Characteristics
The study population included 117 males and 40 fe-
males, diagnosed between 1980 and 2007. The median age
was 67 years (range, 35–88 years), and occupational expo-
sure to asbestos was documented in the majority of patients
by a face-to-face questioning (75%). Among this population,
epithelioid subtype was observed in 76% (119 of 157),
sarcomatoid subtype in 12% (19 of 157), biphasic subtype in
10% (15 of 157), and desmoplastic subtype in 2% (4 of 157).
In 75% of the cases, information on the administered treat-
ment could be retrospectively collected. Among the 124
documented cases, 20 (16%) only received palliative care, 37
(30%) had surgery (extrapleural pneumectomy in 21 [17%],
lung sparing surgery, i.e., cytoreduction in 16 [13%]), 70
(56%) had chemotherapy, and radiotherapy was performed in
69 (56%). In 38% of cases, patients were enrolled in clinical
trials. Chemotherapy regimen was an association of pem-
etrexed/platinum in 59% of the patients. Due to the absence
of surgery in 70%, International Mesothelioma Interest
Group staging was not reliable and therefore not available for
the survival analysis.
The overall study population had a median overall
survival of 18 months, and the 2-year survival rate was 38%,
95% confidence interval 29 to 46%.
In the 157 MPM, c-MET Subcellular
Localization Is Correlated to the Staining
Intensity
Normal cell (epithelial cells, macrophages, and smooth
muscular cells) showed reactivity for c-MET and were used
as internal controls. Stromal cells also occasionally reacted
positively for c-MET. Among the 157 cases positive, c-MET
expression was found in 119 MM (76%), mostly of epitheli-
oid type (87%, p 0.0001). The staining intensity, illustrated
in Figure 1, varied markedly among MPM samples and
within the same slide, with a pattern from strong to faint (42,
37, and 40 slides of strong [I3], moderate [I2], and weak [I1]
intensity, respectively).
Surprisingly, various subcellular localization of the
c-MET staining was observed at plasma membrane (56%),
diffuse in the cytoplasm of mesothelioma cells (25%) or both
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at plasma membrane and in the cytoplasm (19%) (Figure 2).
This c-MET subcellular localization also varied according to
staining intensity. When expression was weak (approxi-
mately 75% of the slides exhibiting I1 intensity), the staining
was mainly observed in the cytoplasm of mesothelioma cells.
On the contrary, when c-MET expression was strong (90% of
the slides exhibiting I3 intensity), it was mostly observed at
cell membrane (p  0.0001) (Figure 3).
Among the 119 positive c-MET specimens, 77 (65%)
were also positive for phospho-c-MET, the active form of
c-MET. It should be noticed that phospho-c-MET scoring
was significantly correlated to c-MET scoring (2 test, p 
0.035). As described for c-MET staining, phospho-c-MET
staining intensity varied markedly among MPM samples and
within the same slide, with a pattern from strong to faint.
Moreover, phospho-c-MET staining was observed at plasma
membrane, or diffuse in the cytoplasm of mesothelioma cells,
and also in the nuclei of these cells. Interestingly, strong
intensity of phospho-c-MET staining was only observed for
plasma membrane, while the cytoplasmic phospho-c-MET
staining was mainly of weak intensity (82% of the cytoplas-
mic staining).
Both c-MET and phospho-c-MET scoring were inde-
pendent of patient gender (2 test, p  0.98 and p  0.36,
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FIGURE 1. Representative inten-
sity of c-MET or phospho-c-MET
immunostaining in malignant pleu-
ral mesothelioma (MPM). MPM
tumors were stained with anti-c-
MET (upper panels) or phospho-c-
MET (lower panels) antibody as
described in the “Patients and
Methods” section. Pictures illustrate
representative intensities: weak (I1),
moderate (I2), and strong (I3)
measured. Internal positive controls
were normal epithelial cells.
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FIGURE 2. Representative subcellular localization of phospho-
c-MET immunostaining in malignant pleural mesothelioma
(MPM). MPM tumors were stained with antiphospho-c-MET
antibody as described in the “Patients and Methods” section.
Pictures illustrate representative subcellular localization ob-
served. Internal positive controls were normal epithelial cells.
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FIGURE 3. c-MET subcellular localization according its im-
munostaining intensity. Malignant pleural mesothelioma
(MPM) tumors were stained with anti-c-MET antibody as
described in the “Patients and Methods” section. For each
intensity, set of histogram represent percentage of case
number counted in each subcellular compartment.
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FIGURE 4. Nuclear translocation of phospho-
c-MET in HBEC3 cells under hepatocyte growth
factor (HGF) stimulation. HBEC3 cells were cul-
tivated for 24 hours in KSFM devoid of EGFr
and BPE, then stimulated 5, 10, 15, or 20 min-
utes with HGF (40 ng/ml) or not. A, Confocal
laser scanning images of HBEC3 cells stained
for c-MET, phospho-c-MET, or alpha-tubulin
followed by a Texas-red-conjugated secondary
antibody. Scale bar  50 m. B, Representative
Western blot performed with antiphospho-c-
MET antibody (see Patients and Methods sec-
tion) and its analyses. Ratios of phospho-c-MET
expression compared with the normalizer of
each fraction were determined in three sepa-
rate cultures. Values are mean  SEM. Positive
control is extract from H1975 cell line.
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respectively) or age (2 test, p  0.30 and p  0.62,
respectively).
c-MET Subcellular Localization in HBEC3
Depend on Its Activation
To further analyze the physiological significance of
subcellular localizations of the c-MET protein and its active
form phospho-c-MET, we investigate the c-MET subcellular
localization with or without HGF stimulation in an epithelial
bronchial cell line, the HBEC3 cells. In fact, conversely to
mesothelioma models, HBEC3 cells, immortalized but unable
to grow in agar and nontumorogenic, did not accumulate
multiple genetic abnormalities that could interfere with c-
MET functions and therefore reflect a more physiological
epithelial cell model. Cells were cultivated for 24 hours in
KSFM devoid of EGFr and BPE and then stimulated 5, 10,
15, or 20 minutes with HGF (40 ng/ml) or not. Immunocyto-
fluorescence collected from HBEC3 cells stimulated with the
HGF is shown in Figure 4A, while c-MET protein detection
by Western blot is shown in Figure 4B.
At T0, i.e., for unstimulated cells, c-MET staining is
localized mainly to cells plasma membrane and weakly to
cytoplasm. Unstimulated HBEC3 also exhibit immunoreac-
tivity for phospho-c-MET, but this staining is weak and
diffuse. At T5, c-MET staining is dispatched between cells
membrane, cytoplasm compartment, and nucleus. From T10
to T20 of the HGF stimulation, both c-MET and phospho-c-
MET nuclear staining increased gradually with the HGF
stimulation delay. A weak c-MET cell membrane staining
was still observed at T20.
To check that nuclear translocation of phospho-c-MET
did not result from a staining artifact both in pathological
specimens and in our epithelial cell model, we performed
subcellular fractionation. Figure 4B shows the Western blot
analysis of phospho-c-MET expression in nuclear fraction of
HBEC3 cells, previously devoid of EGFr and BPE during 24
hours, and stimulated by HGF (40 ng/ml) until 20 minutes. At
T10, a marked increase in phosphorylated c-MET is observed
in the nuclear fraction of HBEC3 cells (signal threefold
stronger than signal measured at T0, i.e., in control cells).
This increase is confirmed at T20, the phosphorylated c-MET
pool being sixfold greater than that measured at T0. This
increase is not concomitant with a decrease of c-MET signal
in the cytoplasmic fraction nor of c-MET signal in membrane
compartment, which seems constant (data not shown).
It should be noted that contamination of a fraction by
another was tested by hybridizing each of the fraction studied
with the internal control of the other. Such contamination
could not account for phospho-c-MET modification reported
in nuclear fraction.
c-MET Intensity Staining or Subcellular
Localization and MPM Survival Outcome
Among all the demographic, clinical, and molecular
variables studied in univariate analysis, only the age at
diagnosis, the histological subtype, the c-MET and phospho-
c-MET intensities, the c-MET localization, and the c-MET
scoring had a prognosis value at a risk cutoff of 10%.
Influence of the variable intensity of c-MET staining on
overall survival in MM is shown in Figure 5. In patients with
a c-MET intensity staining higher than 1, median OS was 25
months versus 13 months for other patients (log-rank test,
p  0.0016).
As shown in Figure 6, in patients with specimens
showing a c-MET pool exclusively confined to plasma mem-
brane, median OS was 25 months versus 11 months for
cytoplasmic or 13 months for both subcellular localizations
(log-rank test, p  0.02). Neither phospho-c-MET scoring
nor phospho-c-MET localization discriminate patients sub-
groups with different median OS.
The best multivariate Cox regression model took into
account the histological subtype, the c-MET intensity, and
localization and was stratified on the age at diagnosis. The
variables phospho-c-MET intensity and c-MET scoring were
excluded of the model due to their correlation with the
c-MET intensity. The results of this model are shown in
Table 1. In multivariate analysis, the c-MET localization and
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FIGURE 5. c-MET intensity staining (IS) relationship with
overall survival rate. The overall survival rate curve for the
157 patients from the MESOPATH group is presented ac-
cording to c-MET intensity staining expression.
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the histological type were significant at a 5% risk cutoff and
at a 10% risk cutoff, respectively. For the 1 year-survival, the
worst prognosis factors c-MET was localized restrictively at
the plasma membrane (adjusted HR  2.9) and in epithelioid
type (adjusted HR  2.7).
DISCUSSION
Herein, we investigate the correlation between tumor
expression of both c-MET and its activated form, phospho-
c-MET, and OS in a series of 157 MPM specimens from the
MESOPATH group. The originality of our work was to assay
concomitantly subcellular distribution of c-MET and phos-
pho-c-MET.
In line with data reporting an increase in protein ex-
pression of c-MET in 80% of mesothelioma tested,2 this work
reports that c-MET expression is frequently detected by
immunohistochemistry in patients with MPM (71.9% of the
157 cases). We confirmed that normal epithelial cells and
adjacent lung adenocarcinomas both show strong luminal
c-MET staining, while basal bronchial cells, progenitors for
the bronchial epithelium, showed no such polarized stain-
ing.12 This observation was also reported in pancreas19 and
breast.20 As HGF is known to induce tubulogenesis, it
might specifically act as an epithelial differentiating factor
during development. Consistent with this hypothesis, we
observed more frequent c-MET staining in epithelioid
subtype of MPM.
Furthermore, our analysis revealed that in MPM cells,
subcellular distribution of c-MET or its phosphorylated form
correlates with its expression level: localization to the plasma
membrane is described for high level, while this localization
is cytoplasmic when the expression is weak. Moreover, we
reported that c-MET strongly expressed at cell membrane
from tumor cells and predicts longer overall survival in
patient with MPM. These data should still be validated in an
independent prospective cohort to discard bias of nonuniform
treatment of patients. Such a work is in progress as a part of
the planned ancillary biomarker study of the currently on-
going phase 3 trial IFCT-GFPC 07-01 MAPS (NLM Identi-
fier NCT00651456, Dr. G.Zalcman, PI). In this study, one
explanation for that apparently paradoxical finding could also
come from CD44 cell coexpression, because the HGF-in-
duced c-MET phosphorylation and activation is dependent on
the ectodomain of its coreceptor CD44 splice variant
CD44v6.21,22 CD44 is actually required for the formation of a
ternary complex comprising HGF and c-MET, and activation
of c-MET requires this complex constitution, then leading to
endocytose of the activated phosphorylated receptor. One
could speculate that the balance of c-MET/CD44v6 at cell
surface could alter signal transduction: an increase of mem-
brane c-MET could be the consequence of a lower activation
and endocytosis because of an altered c-MET/CD44v6 inter-
action or a lower expression of CD44v6. Work is in progress
to correlate in this series of specimen c-MET membrane
expression and CD44v6 expression.
Unexpectedly, phospho-c-MET-positive cases often
exhibit a nuclear staining, while c-MET was never detected in
nucleus. One could have argued that such nuclear staining is
an artifact. Thus, we have investigated c-MET translocation
in a bronchial epithelial immortalized but not transformed
cell line, as previous works had only been performed in small
cell lung cancer cells,23 colorectal cancer cells,24 or endothe-
lial-derived cell lines.8 Only, Jagadeeswaran et al. 2 worked
on sarcomatoid- or epithelioid-MPM cancer cell lines, but
dealt with the effect of HGF on cell proliferation, without
studying cell effects of short HGF incubation (15 minutes).
HBEC3 cells are immortalized by cyclin-dependent kinase 4
and human telomerase reverse transcription and have very
few genetic alterations commonly reported in cancer, in
particular mutations of EGFR, K-Ras, PI-3Kinase, B-Raf, or
AKT, up- or downstream signaling proteins of the c-MET
signaling pathway.3 HBEC3 were stimulated up to 20 min-
utes by HGF (40 ng/ml) diluted in culture medium devoid of
EGF and BPE to discard the synergy between the signals
induced by EGF and HGF.3 Cells were not stimulated more
than 20 minutes, as previous works demonstrated that c-MET
TABLE 1. Parameters Influencing Patient 1-yr Prognosis
n
Median OS
(mo)
Univariate Analysis Multivariate Analysis
1-yr Survival
(%) (95% CI)
Log-Rank
Test
Adjusted Hazard
Ratio (95% CI)
Cox Model
Adjusted for Age
Histology
Epithelioid 119 22 72 (63–81) p < 0.0001 1 p  0.095
Nonepithelioid 38 8 42 (26–58) 2.7 (0.8–8.8)
c-MET intensity
0–1 78 13 52 (40–63) p  0.016 p  0.84
2–3 79 25 78 (68–87) 1.1 (0.4–3.3)
c-MET localization
Plasma membrane 63 25 80 (69–90) p  0.02 1 p  0.043
Other 50 13 50 (35–65) 2.9 (1.0–8.2)
Phospho-c-MET localization
Plasma membrane 20 13 51 (27–74) p  0.031 1.6 (0.6–4.5) p  0.29
Other 57 24 78 (66–89) 1
OS, overall survival; CI, confidence interval. Bold values are significant differences.
Journal of Thoracic Oncology • Volume 7, Number 3, March 2012 Prognostic Value of c-MET in Malignant Pleural Mesothelioma
Copyright © 2012 by the International Association for the Study of Lung Cancer 605
phosphorylation is early, with a maximum reached from 4 to
10 minutes according to the authors.8,23 HGF concentration
tested was the concentration commonly described in the
literature.2,8,23,24 We showed by immunocytochemistry and
Western blot that in HBEC3, c-MET receptor has a basal
autophosphorylation activity, as it was previously described
in other cell models.2 Increased c-MET phosphorylation after
HGF stimulation of HBEC3 cells confirms that HBEC3 cells
exhibit a functional c-MET receptor. Interestingly, Western
blot analysis showed after 5 minutes of HGF stimulation that
a decrease of almost 75% of the cytoplasmic signal for
phospho-c-MET occurs before the detection in the nuclear
fraction of this signal at 10 minutes, which may suggest a
translocation of activated receptor between these cellular
compartments. Furthermore, nuclear translocation of phos-
phorylated c-MET receptor has also been assessed by immu-
nocytochemistry. Together, these results provide evidence of
the actual traffic of activated c-MET across cell compart-
ments. The nuclear staining of phospho-c-MET reported in
MPM pathological specimens thus seems to reflect a physi-
ological receptor tyrosine kinase cell traffic.
In conclusion, our results strongly suggest that immu-
nodetection of c-MET receptor-tyrosine kinase specifically at
plasma membrane could be relevant to predict prognosis of
patients with MPM. Whether these patients could benefit
from c-MET targeted therapies remains to be established in
future prospective clinical trials. In such clinical trials, deter-
mining predictive biomarkers of response and survival would
need systematical study of c-MET expression, activation
state, and subcellular localization and also HGF coreceptors
expression such as CD44 variants or downstream signaling
molecules such as NF2 tumor suppressor gene of which
alteration are frequently described in MPM.
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